U093 JAAD Game Changers
DESCRIPTION
JAAD Game Changers are a selection of landmark articles that have changed the way dermatology is practiced. This forum will consist of short presentations by Game Changer article authors followed by a 15-minute interchange with the audience to ask the authors questions about their ground-breaking work. The selected top 10 Game Changers over the last 2 years of JAAD will be presented. At the end of this session, the audience will use an Audience Response System to vote for "JAAD Game Changer of the Year."
LEARNING OBJECTIVES
Summarize selected seminal JAAD publications of the previous 2 years.
Discuss the publications focusing on application of knowledge to the diagnosis, management, and treatment of dermatologic disease.
Promote academic interchange with the authors of selected publications to improve retention of information.
SCHEDULE
7:30 AM
Introduction
Wendi E. Wohltmann, MD, FAAD, Eden Louise Pappo Lake, MD, FAAD
7:32 AM
Clinical features and natural course of pediatric longitudinal melanonychia: A retrospective cohort study in Korea
Si-Hyung Lee
7:36 AM
A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus
Gil Yosipovitch, MD
7:40 AM
External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database
Caleb (Steven) Freeman, MD, FAAD
7:44 AM
Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: A multicenter randomized controlled trial
Shima Ahmady, MD
7:48 AM
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study
Lukas Flatz, MD
7:52 AM
Negative impact of comorbidities on all-cause mortality of patients with psoriasis is partially alleviated by biologic treatment: A real-world case-control study
Robert Gniadecki, MD
7:56 AM
Benzoyl peroxide for acne treatment is not associated with an increased risk of malignancy: a retrospective cohort study
Christopher Thang
8:00 AM
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis
Amy S. Paller, MD, FAAD
8:04 AM
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2
Brett King, MD, PhD, FAAD
8:08 AM
Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma metastasis and clinical outcomes
Bryan T. Carroll, MD, PhD, FAAD
8:12 AM
Interactive audience question & answer session with all Game Changer authors
8:27 AM
Selection of JAAD Game Changer of the Year via ARS/Closing remarks
Wendi E. Wohltmann, MD, FAAD, Eden Louise Pappo Lake, MD, FAAD
DIRECTOR
Wendi E. Wohltmann, MD, FAAD
CO-DIRECTOR
Eden Louise Pappo Lake, MD, FAAD
SPEAKERS
Shima Ahmady, MD
Bryan T. Carroll, MD, PhD, FAAD
Lukas Flatz, MD
Caleb (Steven) Freeman, MD, FAAD
Robert Gniadecki, MD
Brett King, MD, PhD, FAAD
Si-Hyung Lee
Amy S. Paller, MD, FAAD
Christopher Thang
Gil Yosipovitch, MD
HANDOUTS
DISCLOSURES
Shima Ahmady, MD
No financial relationships exist with ineligible companies.
Bryan T. Carroll, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Lukas Flatz, MD
No financial relationships exist with ineligible companies.
Caleb (Steven) Freeman, MD, FAAD
No financial relationships exist with ineligible companies.
Robert Gniadecki, MD
No financial relationships exist with ineligible companies.
Brett King, MD, PhD, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Amgen – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Aquestive Therapeutics – Consultant (1099 relationship)(Fees); BiologicsMD, Inc. – Consultant(Stock Options); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Eli Lilly and Company – Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Galderma – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria), Consultant(Fees), Data Safety Monitoring Board(Fees); Leo Pharma – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Fees), Advisory Board(Honoraria), Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Q32 Bio Inc. – Consultant (1099 relationship)(Fees); Regeneron – Advisory Board(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Sanofi Genzyme – Speaker(Honoraria); Soterios Pharma – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant(Fees), Investigator(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); TWi Biotechnology, Inc. – Consultant(Fees);
Si-Hyung Lee
No financial relationships exist with ineligible companies.
Amy S. Paller, MD, FAAD
AbbVie – Data Safety Monitoring Board(Honoraria), Investigator(Grants/Research Funding); Abeona Therapeutics – Data Safety Monitoring Board(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); BioCryst Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Honoraria); BioMendics, LLC – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); Castle Creek Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Chiesi Farmaceutici – Consultant (1099 relationship)(Honoraria); Daiichi Sankyo – Data Safety Monitoring Board(Honoraria); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Galderma – Data Safety Monitoring Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Krystal Biotech, Inc – Consultant(Honoraria); L'Oréal France – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Pelthos Therapeutics – Consultant (1099 relationship)(Honoraria); Quoin Pharmaceuticals Ltd – Consultant (1099 relationship)(Honoraria); Regeneron – Consultant(Honoraria), Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Eden Louise Pappo Lake, MD, FAAD
No financial relationships exist with ineligible companies.
Christopher Thang
No financial relationships exist with ineligible companies.
Wendi E. Wohltmann, MD, FAAD
No financial relationships exist with ineligible companies.
Gil Yosipovitch, MD
AbbVie – Advisory Board(Honoraria); Arcutis, Inc. – Advisory Board(Honoraria); Cara Therapeutics – Advisory Board(Honoraria); CeraVe – Advisory Board(Honoraria); Eli Lilly – Investigator(Fees), Investigator(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Honoraria); escient – Investigator(Fees), Investigator(Grants/Research Funding); Galderma – Advisory Board(Honoraria); Galderma Laboratories, L.P. – Consultant(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding); GSK – Advisory Board(Honoraria); Kamari Pharma – Consultant(Fees); Kiniksa Pharmaceuticals, Ltd. – Investigator(Grants/Research Funding); Maruho Co., Ltd – Speaker/Faculty Education(Fees); Novartis – Consultant(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pierre Fabre – Consultant(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding); Vifor Pharma – Consultant(Fees);